is an associate at Axinn, Veltrop & Harkrider LLP. Rebecca’s practice focuses on intellectual property counseling and litigation, particularly within the pharmaceutical industry. Her litigation experience includes patent litigation of pharmaceutical cases under the Hatch-Waxman Act.
For more information or to contact Rebecca, please visit her Firm Profile Page.
The University of California (“UC”) and The Broad Institute, Inc. (“Broad”) are among the leaders in the development of CRISPR technology. Both UC and Broad filed patent applications for claims broadly drawn to CRISPR-Cas9 systems and methods of DNA editing. These parties are currently engaged in litigation over patents concerning the potentially most lucrative application of CRISPR technology – the use of CRISPR-Cas9 in plant and animal (eukaryotic) cells. The outcome of this litigation will affect control of the CRISPR platform and development of the technology.